Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 260-268

  Wang, Fengli ^a   Li, Qiongshu ^a   Ni, Weihua ^a   Fang, Fang ^a,b   Sun, Xiaxia ^a   Xie, Fei ^a   Wang, Juan ^a   Wang, Fang ^a   Gao, Sujun ^c   Tai, Guixiang ^a  

^a Basic Medical College   (China)

^b JILIN MEDICAL COLLEGE   (China)

^c JILIN UNIVERSITY   (China)

Author keywords

B16; Growth inhibition; Migration; Mucin 1; Proliferation

Indexed keywords

BETA CATENIN; CYCLIN D1; MUCIN 1; MYC PROTEIN; ONCOPROTEIN; T CELL FACTOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CLONE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE BETA CATENIN; ONCOGENE C MYC; ONCOGENE CYCLIN D1; ONCOGENE MUC1; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; TUMOR INVASION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; BETA CATENIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D1; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MUCIN-1; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-MYC; TCF TRANSCRIPTION FACTORS;

EID: 84878181734     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2440     Document Type: Article

References (45)

1. Kufe DW: Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9: 874-885, 2009.
2. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchel J: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823, 1988.
3. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV and Hilkens J: Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 267: 6171-6177, 1992.
4. Kufe DW: Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther 7: 81-84, 2008.
5. Li Y, Bharti A, Chen D, Gong J and Kufe D: Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 18: 7216-7224, 1998. (Pubitemid 28533041)
6. Li Y, Kuwahara H, Ren J, Wen G and Kufe D: The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 276: 6061-6064, 2001.
7. Ren J, Li Y and Kufe D: Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 277: 17616-17622, 2002. (Pubitemid 34967564)
8. Raina D, Ahmad R, Kumar S, et al: MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 25: 3774-3783, 2006. (Pubitemid 44300263)
9. Wei X, Xu H and Kufe D: Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 7: 167-178, 2005. (Pubitemid 40248342)
10. Wei X, Xu H and Kufe D: MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 21: 295-305, 2006. (Pubitemid 43099944)
11. Wei X, Xu H and Kufe D: Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res 67: 1853-1858, 2007. (Pubitemid 46383412)
12. Yamamoto M, Bharti A, Li Y and Kufe D: Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 272: 12492-12494, 1997. (Pubitemid 27203339)
13. Huang L, Chen D, Liu D, Yin L, Kharbanda S and Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 65: 10413-10422, 2005. (Pubitemid 41743735)
14. Ahmad R, Raina D and Trivedi V et al: MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signaling. Nat Cell Biol 9: 1419-1427, 2007. (Pubitemid 350201755)
15. Hu XF, Yang E, Li J and Xing PX: MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Rev Anticancer Ther 6: 1261-1271, 2006. (Pubitemid 44304694)
16. Kufe DW: Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 8: 1197-1203, 2009.
17. Shin CY, Park KH, Ryu BK, Choi EY, Kim KC and Ko KH: Squamous differentiation downregulates Muc1 mucin in hamster tracheal surface epithelial cell. Biochem. Biophys Res Commun 271: 641-646, 2000. (Pubitemid 30444681)
18. Ligtenberg MJ, Buijs F, Vos HL and Hilkens J: Suppression of cellular aggregation by high levels of episialin. Cancer Res 52: 2318-2324, 1992.
19. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A and Hilkens J: Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129: 255-265, 1995.
20. Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K and Hollingsworth MA: Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 88: 507-518, 2000.
21. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G and Hugh JC: The breast mucin MUC1 as a novel adhesion ligand for endothelial intracellular adhesion molecule 1 in breast cancer. Cancer Res 56: 4244-4249, 1996. (Pubitemid 26305023)
22. Agrawal B and Longenecker BM: MUC1 mucin-mediated regulation of human T cells. Int Immunol 17: 391-399, 2005. (Pubitemid 40568114)
23. Li Y, Liu D, Chen D, Kharbanda S and Kufe D: Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 22: 6107-6110, 2003. (Pubitemid 37175889)
24. Huang L, Ren J, Chen D, Li Y, Kharbanda S and Kufe D: MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther 2: 702-706, 2003.
25. Raina D, Ahmad R, Chen D, Kumar S, Kharbanda S and Kufe D: MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther 7: 1959-1967, 2008.
26. Li Y, Ahmad R, Kosugi M, et al: Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol 78: 166-174, 2010.
27. Raina D, Kosugi M, Ahmad R, et al: Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 10: 806-816, 2011.
28. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD and Gendler SJ: MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22: 1324-1332, 2003. (Pubitemid 36384593)
29. Hattrup CL and Gendler SJ: MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Res 8: R37, 2006.
30. Costa NR, Paulo P, Caffrey T, Hollingsworth MA and Santos-Silva F: Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line. PLoS One 6: e26970, 2011.
31. Yuan Z, Liu X, Wong S, Machan JT and Chung MA: MUC1 knockdown with RNA interference inhibits pancreatic cancer growth. J Surg Res 157: e39-e46, 2009.
32. Schroeder JA, Masri AA, Adriance MC, et al: MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 23: 5739-5747, 2004. (Pubitemid 39093019)
33. Brossart P, Schneider A, Dill P, et al: The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61: 6846-6850, 2001. (Pubitemid 32896509)
34. Yuan Z, Wong S, Borrelli A and Chung MA: Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun 362: 740-746, 2007. (Pubitemid 47368156)
35. Gao J, McConnell MJ, Yu B, et al: MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 35: 337-345, 2009.
36. Kufe D: Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene 29: 5663-5666, 2010.
37. Retterspitz MF, Mönig SP, Schreckenberg S, et al: Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res 30: 4635-4641, 2010.
38. Lillehoj EP, Lu W, Kiser T, Goldblum SE and Kim KC: MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism. Biochim Biophys Acta 1773: 1028-1038, 2007. (Pubitemid 46901085)
39. Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999. (Pubitemid 29180374)
40. Sutherland RL and Musgrove EA: Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 4: 14-17, 2002. (Pubitemid 34097551)
41. Lavergne E, Hendaoui I, Coulouarn C, et al: Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-catenin. Oncogene 30: 423-433, 2011.
42. Wijnhoven BP, Dinjens WN and Pignatelli M: E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 87: 992-1005, 2000. (Pubitemid 30496847)
43. Premaratne P, Welén K, Damber JE, Hansson GC and Bäckström M: O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model. Tumour Biol 32: 203-213, 2011.
44. Cascio S, Zhang L and Finn OJ: MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain. J Biol Chem 286: 42248-42256, 2011.
45. Spicer AP, Parry G, Patton S, and Gendler SJ: Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. J Biol Chem 266: 15099-15109, 1991. (Pubitemid 21907624)